Sponsor Dossier
UCB
Sponsor Dossier for UCB. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: Bimzelx
- Brand: BRIVIACT
- Brand: CIMZIA
- Brand: FINTEPLA
- Brand: KEPPRA
- Brand: NEUPRO
- Brand: RYSTIGGO
- Brand: VIMPAT
- Device (sponsor): Swab
About
UCB Pharma Division of UCB is an Australian Private Company with ABN 48005799208, registered in Victoria. The entity is active and registered for GST.
Portfolio
UCB has 10 brands on the ARTG, of which 9 are indexable and 9 carry a Product Information document. 9 brands are PBS-listed, 9 have a PBAC outcome on record, and 6 have an AusPAR on record. Notable brands include Bimzelx, BRIVIACT, CIMZIA, FINTEPLA, KEPPRA, NEUPRO, RYSTIGGO, VIMPAT, XYZAL, ZILBRYSQ.
Therapeutic focus
— Neurology: 7 brands — Immunology: 3 brands
PBS footprint
9 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2026-07-01, across 9 brands with a PBAC outcome on record. The latest AusPAR is 2025-08-04, across 6 brands with an AusPAR on record.